LEO Pharma appoints Elisabeth Svanberg new member of its Board of Directors
28.6.2022 08:00:00 CEST | LEO Pharma | Press release
Elisabeth Svanberg currently serves as member of the Board of Directors at Amolyt SA, Galapagos SA and Egetis Therapeutics AB. Since 2016 she has served as Chief Development Officer at Ixaltis SA and since 2020 as Chief Medical Officer at Kuste Biopharma. She has previously held global positions with Janssen Pharmaceuticals (a Johnson & Johnson company), Bristol-Myers Squibb and MERCK-SERONO.
- Elisabeth Svanberg brings extensive biotech and pharmaceutical experience from a multinational environment, that will be of great value for LEO Pharma in setting direction for launching new innovative treatments on the global market and in creating future growth. I look much forward to working together with Elisabeth going forward, said Jesper Brandgaard, chairman of the Board of Directors at LEO Pharma.
Elisabeth Svanberg has demonstrated success in product development in different therapeutic areas and development phases regulated by both FDA, EMA, CFDA and PMDA. She is recognized for successfully translating strategic goals into practical implementation by establishing high performing cross-functional teams in global networks and championing collaboration across functions to accelerate business results
- LEO Pharma is at a very exciting time of its development going from a traditional pharmaceutical company to a globally focused player in the innovative biotech space. It is an exciting time to join the Board of Directors and I look forward to contribute to paving the way for future success, said Elisabeth Svanberg.
Elisabeth Svanberg is Associated Professor of Surgery and holds a MD (MD License 1990) and a PhD in Surgical Sciences from University of Gothenburg, Sweden.
Contacts
Contact:
Henrik Heskjær
hdtdk@leo-pharma.com
+45 3140 6180
About LEO Pharma
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma delivers 11% revenue growth at CER and achieves strategic milestones16.11.2026 10:00:00 CET | Pressemeddelelse
Ballerup, Denmark, 16 November, 2026 - In 9M 2026, LEO Pharma delivered strong innovation-led growth, with a significantly improved gross margin and continued investment in innovation. In September, LEO Pharma completed the acquisition of dersimelagon, an investigational first-in-class oral therapy now under FDA Priority Review, marking an important strategic milestone. Momentum continued after the period, with new approvals for Anzupgo® in Europe and China, further extending the product’s reach and underscoring LEO Pharma’s commitment to advancing innovation in dermatology. Financial highlights LEO Pharma’s revenue increased by 9% to DKK 10,961 million for 9M 2026, and by 11% at constant exchange rates (CER). The revenue growth was led by North America (38% at CER) with Rest of World (10% at CER) and Europe (1% at CER) also contributing. Revenue from the Dermatology portfolio grew by 13% (CER), driven by the Innovative brands Anzupgo®, Spevigo® and Adtralza®/Adbry®, which combined had
LEO Pharma announces NMPA-approval of Anzupgo® (delgocitinib) cream for patients with moderate to severe chronic hand eczema (CHE) in China13.11.2026 08:00:00 CET | Pressemeddelelse
Anzupgo® (delgocitinib) cream has been approved by China’s National Medical Products Administration (NMPA) for adult patients with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate. The approval is supported by positive results from the DELTA China phase 3 trial, together with the broader delgocitinib clinical program, including DELTA 1, DELTA 2, DELTA 3 and DELTA Force.1-7 The approval reflects LEO Pharma’s commitment to improving care for adults living with moderate to severe chronic hand eczema in China, an exciting and important market for the company.
LEO Pharma presents new data on delgocitinib cream at EADV 2026 highlighting real-world outcomes in adults and new adolescent data in Chronic Hand Eczema (CHE)1.10.2026 12:00:00 CEST | Pressemeddelelse
Interim results from the German REACHED study provide the first real-world evidence on the effectiveness of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema (CHE), with 28.6% of patients assessed as clear or almost clear after eight weeks of treatment, from none at baseline.1 New post hoc analyses from the phase 3 DELTA TEEN trial show greater reductions in daily HESD itch and pain scores with delgocitinib cream than with cream vehicle in adolescents aged 12-17 with moderate to severe CHE.2 In an oral presentation, new post hoc analyses from DELTA TEEN show that a higher proportion of adolescents reported no impact on quality of life at Week 16 with delgocitinib cream than with cream vehicle (27.0% vs 0%)3
LEO Pharma presents new tralokinumab data at EADV 2026 highlighting real-world outcomes and quality of life in adults and adolescents with atopic dermatitis (AD) involving high-burden areas1.10.2026 10:30:00 CEST | Pressemeddelelse
New findings from a subgroup analysis of the 12-month TRACE study show that more than 70% of adults whose Atopic Dermatitis (AD) affected multiple high-burden areas – such as the head and neck, hands and feet, or genitals – had reduced involvement of those areas after 12 months of treatment with tralokinumab.1 New pre-specified and post hoc analyses from the phase 3 ADHAND trial show significantly greater improvements in quality of life, daily function and sleep at Week 16 with tralokinumab monotherapy than with placebo in adults with AD and moderate-to-severe hand involvement, with the two treatment groups separating within two weeks.2,3 In a post hoc analysis, adolescents aged 12-17 years treated across the phase 3 ECZTRA 6 trial and its ECZTEND extension, response rates remained high and stable through most of the extension period, and no new safety concerns were identified.5
LEO Pharma to showcase its broadest ever scientific program at EADV 202624.9.2026 09:00:00 CEST | Pressemeddelelse
LEO Pharma will present 28 accepted abstracts at the 2026 European Academy of Dermatology and Venereology Congress, taking place from 30 September to 3 October in Vienna, Austria. The EADV 2026 program reflects the strength and breadth of LEO Pharma’s portfolio, showcasing what’s now and what’s next in medical dermatology with new evidence across nine disease areas, six routes of administration and nine modes of action; including biologic injectables, topical formulations, and covering data across established dermatology brands and new innovation. The program underscores LEO Pharma’s continued commitment to advancing medical dermatology through evidence that addresses both highly prevalent chronic skin diseases and complex or rare, hard-to-treat conditions with significant unmet needs.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
